Modafinil

• Narcolepsy
• Obstructive Sleep Apnea
• Shift Work Disorder
• Excessive Daytime Sleepiness

Modafinil (Provigil) is a wakefulness-promoting agent (eugeroic) approved for excessive daytime sleepiness associated with narcolepsy, residual sleepiness in obstructive sleep apnea despite adequate CPAP therapy, and shift work disorder. It has been in clinical use since the late 1990s and remains a backbone non-stimulant option, with armodafinil — its longer-acting R-enantiomer — as a closely related alternative. Modafinil is a Schedule IV controlled substance, reflecting a genuine but lower abuse potential than amphetamines, and is meaningfully less likely than traditional stimulants to disturb evening sleep onset when dosed correctly in the morning.

Mechanism of Action

Modafinil's molecular target spectrum is broader than originally appreciated. The most consistent finding is binding to and weak inhibition of the dopamine transporter (DAT), increasing extracellular dopamine in the striatum, nucleus accumbens, and prefrontal cortex without triggering the vesicular dopamine release responsible for amphetamine-type euphoria and rebound. Modafinil also raises norepinephrine via NET inhibition in the prefrontal cortex and locus coeruleus, increases histamine release from the tuberomammillary nucleus, indirectly activates orexin/hypocretin neurons in the lateral hypothalamus, and modulates GABAergic and glutamatergic tone in sleep–wake regulatory regions.

The net effect is a stable elevation of arousal-promoting signaling across multiple ascending arousal systems. Clinically, this translates into improved vigilance, reaction time, working memory, and subjective alertness during the biological day, with relatively little peripheral sympathomimetic activation. Compared with amphetamines, modafinil produces a smoother time–effect curve, less appetite suppression, less cardiovascular activation, and far less rebound fatigue or dysphoria. The orexin component is mechanistically interesting because narcolepsy type 1 is caused by orexin neuron loss; modafinil does not replace lost orexin but appears to enhance signaling in the residual circuitry. The NIH narcolepsy resource summarizes current understanding of the disease and treatment landscape.

Clinical Use

For narcolepsy without cataplexy, modafinil is a reasonable first-line wakefulness-promoting agent, especially when patients prefer to avoid controlled stimulants or have a history of substance misuse. The American Academy of Sleep Medicine guideline supports modafinil as a strong recommendation for narcolepsy. For obstructive sleep apnea, modafinil is approved only as an adjunct: CPAP fit, mask leak, pressure titration, and adherence must be optimized first, because untreated apnea continues to drive cardiovascular risk regardless of how alert the patient feels. For shift work disorder, dosing is timed to the start of the work shift rather than the clock.

Alternatives include armodafinil (longer half-life, often allowing once-daily dosing), the wake-promoting agent solriamfetol, the histamine H3 inverse agonist pitolisant, and the traditional stimulants methylphenidate and amphetamine salts. Compared with stimulants, modafinil typically produces smaller absolute Maintenance of Wakefulness Test gains in profoundly sleepy patients but better tolerability and a flatter daily profile. Patient selection should weigh cardiovascular history (avoid in significant left ventricular hypertrophy or recent ischemia), prior psychiatric stability, and any history of skin reactions. Common off-label uses include multiple sclerosis fatigue, chemotherapy-related fatigue, and depression augmentation, though evidence for these is mixed and insurance coverage often requires demonstration of failure on first-line therapy. The medication has also become a frequently misused cognitive enhancer in academic and professional settings; this off-label use is not supported by adequate efficacy data in healthy individuals and carries the same skin and psychiatric risks as legitimate use. Our neurologic and pulmonary services frequently coordinate evaluation when residual sleepiness is multifactorial, and we routinely screen for reversible contributors including iron deficiency, hypothyroidism, untreated depression, alcohol use, and sedating medications before recommending pharmacologic wakefulness promotion. The St. Pete senior sleep apnea guide and the screen time and sleep article cover common reasons sleep quality and CPAP outcomes underperform.

How to Take It

For narcolepsy and OSA, take 200 mg by mouth once daily in the morning, ideally within an hour of waking and at the same time each day; some patients benefit from 400 mg, though the additional gain over 200 mg is modest. For shift work disorder, take 200 mg about one hour before the start of the shift. Modafinil can be taken with or without food, though a large fatty breakfast can delay onset by an hour or so without changing total absorption. If a dose is forgotten and it is still early in the day, take it; if it is late afternoon or evening, skip the day rather than risk insomnia.

The first week typically brings a mild headache, dry mouth, and a sense of being more focused than rested — this is expected. Caffeine is best reduced rather than added on top, and alcohol blunts the wakefulness benefit while worsening next-day sluggishness. Hormonal contraception becomes less reliable; an additional non-hormonal method is recommended during therapy and for one month after discontinuation. Patients should plan their dosing around any travel across time zones to maintain a stable circadian alignment, and shift workers should keep their dosing tied to the start of each shift rather than to clock time. Store tablets at room temperature in the original container away from heat and humidity, and never share the medication because individual response and cardiovascular tolerability vary substantially.

Monitoring and Follow-Up

A follow-up at 2 to 4 weeks confirms tolerability, screens for rash, and lets the prescriber adjust the dose between 200 and 400 mg. Blood pressure and resting heart rate are checked at baseline and at every visit; a sustained systolic increase of more than 10 mmHg or heart rate consistently above 100 bpm warrants dose reduction. Annual labs include a CBC, comprehensive metabolic panel for liver enzymes (AST and ALT should remain under approximately 3 times the upper limit of normal), and a focused cardiovascular history. Mood screening at every visit looks for emergent anxiety, mania, or psychosis, all of which are dose-related and reversible with discontinuation. CPAP download data should be reviewed at least annually for OSA patients, with a target of at least 4 hours nightly on 70 percent of nights before continuing modafinil long-term. Treatment efficacy is assessed not only by patient self-report but also by objective measures including Epworth Sleepiness Scale (target reduction of at least 4 points or final score below 10), driving incident history, work or academic performance, and partner-reported alertness. If meaningful improvement is not evident by 8 to 12 weeks at the maximum tolerated dose, the underlying diagnosis should be reconsidered and other contributors to fatigue revisited rather than escalating further.

Special Populations

Elderly patients clear modafinil more slowly and are more sensitive to insomnia, agitation, and blood pressure rise; starting at 100 mg daily is reasonable. Renal impairment requires no specific adjustment (elimination is hepatic), but severe hepatic impairment warrants halving the dose. Pregnancy data from a manufacturer registry suggest a possible increase in major congenital malformations including cardiac defects, so modafinil is generally avoided in pregnancy and effective non-hormonal contraception is recommended. Lactation use is not advised. Pediatric use is not approved; serious skin reactions including Stevens-Johnson syndrome occurred in pediatric clinical trials and led to a clear pediatric warning. Patients with mitral valve prolapse, recent myocardial infarction, unstable angina, or significant arrhythmia should not receive modafinil. The FDA Provigil label provides the full safety set.

When to Contact Your Doctor

Seek emergency care for any new rash, blistering, mouth or eye sores, peeling skin, or fever with sore throat — these may signal Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS and require immediate discontinuation. Call promptly for chest pain, palpitations lasting more than a few minutes, fainting, severe headache, swelling of the lips or tongue, or trouble breathing. New mania, hallucinations, paranoia, severe anxiety, or thoughts of self-harm warrant urgent evaluation and usually drug discontinuation. Persistent insomnia, weight loss greater than 5 percent of body weight, or a resting heart rate consistently over 100 bpm should prompt a dose review. Any unexpected pregnancy while taking modafinil should be reported promptly so a registry can be informed and the medication discontinued.

If excessive daytime sleepiness is interfering with driving, work, or quality of life, contact us or schedule a visit so our team can confirm the diagnosis, optimize first-line therapy, and decide whether modafinil is the right addition to your regimen.